MaxCyte (MXCT) CEO awarded 600,000 options and 300,000 RSUs

Rhea-AI Filing Summary

MAXCYTE, INC. President and CEO Masoud Maher received an equity compensation package consisting of stock options and restricted stock units. He was granted an option to buy 600,000 shares of common stock at an exercise price of $0.684 per share, expiring on March 26, 2036. Twenty-five percent of these option shares vest on March 27, 2027, with the rest vesting in 36 equal monthly installments, as long as he continues serving the company. He also received 300,000 restricted stock units, each representing one share of common stock. Twenty-five percent of the RSUs vest on March 27, 2027, and the remaining units vest in three equal annual installments, again contingent on continued service. Following the RSU grant, he holds 475,000 common shares directly. These are compensation-related awards, not open-market purchases or sales.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Masoud Maher

Role President and CEO

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (right to buy)	600,000	$0.00	--
Grant/Award	Common Stock	300,000	$0.00	--

Holdings After Transaction: Employee Stock Option (right to buy) — 600,000 shares (Direct); Common Stock — 475,000 shares (Direct)

Footnotes (1)

1. These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Twenty-five percent (25%) of the RSUs shall vest on March 27, 2027, and the remainder shall vest in three (3) equal annual installments thereafter, subject to the Reporting Person's continued service to the Issuer through each vesting date. Twenty-five percent (25%) of the shares underlying this option shall vest on March 27, 2027, and the remainder shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service to the Issuer through each vesting date.

Key Figures

Stock options granted: 600,000 options Option exercise price: $0.684 per share Option expiration: March 26, 2036 +3 more

6 metrics

Stock options granted 600,000 options Employee Stock Option grant on March 27, 2026

Option exercise price $0.684 per share Exercise price for 600,000-share option grant

Option expiration March 26, 2036 Expiration date of CEO stock option grant

RSUs granted 300,000 RSUs Restricted stock units granted on March 27, 2026

Initial vesting date March 27, 2027 25% of RSUs and options vest on this date

Shares owned after grant 475,000 shares Common stock directly held after RSU award

Key Terms

restricted stock units ("RSUs"), Employee Stock Option, vesting, grant/award acquisition, +1 more

5 terms

restricted stock units ("RSUs") financial

"These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share..."

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

Employee Stock Option financial

"security_title: "Employee Stock Option (right to buy)" for 600000.0000 shares..."

An employee stock option is a promise that lets a worker buy company shares later at a predetermined price, often after they stay for a certain period or meet performance goals — think of it like a coupon that locks in today's price for a future purchase. It matters to investors because options align employees’ incentives with company performance, can increase the number of shares outstanding (dilution) when exercised, and represent a compensation cost that affects reported profits and shareholder value.

vesting financial

"Twenty-five percent (25%) of the RSUs shall vest on March 27, 2027, and the remainder shall vest..."

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

grant/award acquisition financial

"transaction_action: "grant/award acquisition" with transaction_code_description "Grant, award, or other acquisition"..."

exercise price financial

"conversion_or_exercise_price: "0.6840" for the Employee Stock Option grant..."

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Masoud Maher

(Last) (First) (Middle)

C/O MAXCYTE, INC.

9713 KEY WEST AVENUE, SUITE 400

(Street)

ROCKVILLE MARYLAND 20850

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
MAXCYTE, INC. [ MXCT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/27/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/27/2026		A		300,000(1)	A	$0	475,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$0.684	03/27/2026		A		600,000		(2)	03/26/2036	Common Stock	600,000	$0	600,000	D

Explanation of Responses:

1. These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Twenty-five percent (25%) of the RSUs shall vest on March 27, 2027, and the remainder shall vest in three (3) equal annual installments thereafter, subject to the Reporting Person's continued service to the Issuer through each vesting date.

2. Twenty-five percent (25%) of the shares underlying this option shall vest on March 27, 2027, and the remainder shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service to the Issuer through each vesting date.

	/s/ Maher Masoud	03/31/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What equity awards did MAXCYTE (MXCT) CEO Masoud Maher receive?

Masoud Maher received a stock option for 600,000 shares at a $0.684 exercise price and 300,000 restricted stock units. Both awards are part of his compensation and vest over several years, tied to his continued service at MAXCYTE.

How do the new MAXCYTE (MXCT) stock options for the CEO vest?

The 600,000-share stock option vests 25% on March 27, 2027, with the remaining 75% vesting in 36 equal monthly installments. Vesting requires Masoud Maher to remain in service with MAXCYTE through each vesting date, aligning compensation with long-term tenure.

What are the terms of the MAXCYTE (MXCT) CEO’s RSU grant?

Masoud Maher received 300,000 restricted stock units, each equal to one MAXCYTE common share. Twenty-five percent vest on March 27, 2027, and the remaining units vest in three equal annual installments, conditioned on his continued service to the company throughout the schedule.

Did the MAXCYTE (MXCT) CEO buy or sell shares in the market?

No, the Form 4 reports compensation awards, not market trades. The CEO received 600,000 stock options and 300,000 RSUs at no cash cost, with vesting over time. These awards do not represent open-market buying or selling activity by the CEO.

How many MAXCYTE (MXCT) common shares does the CEO hold after these awards?

After the RSU grant, Masoud Maher directly holds 475,000 shares of MAXCYTE common stock. This figure reflects his reported direct ownership following the March 27, 2026 transaction date associated with the compensation awards disclosed in the filing.